While all JAKis increase the risk of VZV infection through the inhibition of JAK1 and thus IFN suppression [11], a systematic review and network meta-analysis showed that IBD patients who receive JAKis are more likely to acquire the infection than those being treated with other biologics [38]. The gene discussed is JAK1; the disease is inflammatory bowel disease.